-->

Tag: ReNeu clinical trial

Home / ReNeu clinical trial

Categories

Mirdametinib is approved by the USFDA for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection

On February 11, 2025, the Food and Drug Administration sanctioned mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients aged 2 years and older di...
reneu-clinical-trial

Scan the code